Therapeutic Of Jiawei Sini Powder On Type ⅢB Chronic Prostatitis (Qi-stagnation And Blood-stasis Type) And Analyze The Relevance With T-lymphocyte Subsets CD3~+、CD4~+

Objective:1.To observe the changes of NIH-CPSI(National Institutes of Health-chronic prostatitis symptom index)score and Traditional Chinese Medicine syndrome score before and after the treatment time of typeⅢB prostatitis with Jiawei Sini Powder,and to evaluate the efficacy.2.To discuss the possible mechanism of Jiawei Sini Powder in the treatment of type IIIB prostatitis from the changes of T-lymphocyte subsets,such as CD3~+and CD4~+,and to further improve the diagnosis and treatment of typeⅢB prostatitis.Methods:About this study,We use the concept of randomization,parallelism,control and openness to design the test method.Through recruitment in the outpatient department of Traditional Chinese Medicine surgery,the outpatient department of andrology,and the inpatient department of the affiliated hospital of Jiangxi University of Traditional Chinese Medicine,60 patients who met the criteria were selected for curative effect observation.60 patients were randomly assigned,one group is the treatment group and the other group is the control group.In each group,there are 30 patients.In terms of treatment,the treatment group took orally jiawei Sini powder,and the control group was given Qianlieshutong capsule.The treatment course of both groups was 28 days.Before treatment,and 28days after treatment,the NIH-CPSI score and Traditional Chinese Medicine syndrome score of patients were counted.The patient’s EPS was taken before and 28 days after treatment to test the changes of CD3~+and CD4~+values.All accidents such as physical discomfort or adverse drug reactions during treatment shall be recorded at any time.Results:1.Baseline value comparison:In the age and course of disease,the comparison showed that there was no significant difference with each group(P>0.05).Before treatment,the NIH-CPSI total score and three sub-scores of pain symptom score,urination symptom score,quality of life score and Traditional Chinese Medicine syndrome score of the two groups were not significantly different (P>0.05).For the analysis of CD3~+and CD4~+in EPS,there was no difference between the two groups before treatment(P>0.05).All baseline data are comparable.2.Between the two groups,comparison of the convalescence rate before and after treatment:The recovery rate of each group after 28days of treatment,the treatment group was 76.7%,and the control group was 40%.The treatment group was more effective(P<0.05).3.Comparison of NIH-CPSI total score and three sub-scores of patients in the two groups before and after treatment:After 28 days of treatment,the two sub-scores of pain and quality of life and the NIH-CPSI total score of patients in the two groups were significantly improved compared with those before treatment(P<0.01),while the treatment group was significantly improved(P<0.05).For the score of urination symptoms,the two groups improved without difference(P>0.05).4.Comparison of Traditional Chinese Medicine syndrome score between the two groups before and after treatment:After 28 days of treatment,the TCM syndrome score decreased in both groups,and the decrease in the treatment group was more obvious(P<0.05).5.Comparison of CD3~+and CD4~+in EPS between the two groups before and after treatment time:After treatment for 28 days,the levels of CD3~+and CD4~+in EPS in the two groups decreased compared with those before treatment.In terms of the degree of decline,the levels of CD3~+in both groups showed no significant decrease,with no difference(P>0.05);the CD4~+levels in both groups decreased significantly,but the degree of decrease in the treatment group was better than that in the control group(P<0.01).6.Comparison of follow-up results:patients with clinical recovery and significant effect were selected from the two groups for follow-up.After 28 days of follow-up,the total NIH-CPSI score,three sub-scores and TCM syndrome score were counted.The analysis showed that compared with before treatment,each group of patients had a significant decrease in various scores after follow-up(P<0.01),but there was no significant difference between the two groups(P>0.05).7.Treatment safety of the two groups of patients:among the 60patients enrolled,one in the treatment group developed mild itching,three patients developed mild diarrhea,and four patients in the control group developed mild rash.In this study stage,all biochemical indicators of the patient are normal without obvious changes,and No side effects caused by drugs.8.Exclusion and drop out:The study progressed smoothly,all the enrolled cases completed clinical study,and no patients were excluded or dropped out.Conclusion:1.Jiawei Sini Powder is significantly better than oral Qianlie Shutong capsule in improving NIH-CPSI score,TCM syndrome score and recovery rate in treating type IIIB prostatitis.2.Jiawei Sini Powder can reduce the levels of CD3~+and CD4~+in EPS,so it is speculated that its mechanism of action in the treatment of type IIIB prostatitis may be through the regulation of the disorder of T-lymphocytes,but the specific mechanism needs further study.